Compare FORTY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | NUVB |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | Israel | United States |
| Employees | N/A | 307 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1998 | N/A |
| Metric | FORTY | NUVB |
|---|---|---|
| Price | $108.00 | $5.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 458.0 | ★ 9.1M |
| Earning Date | 05-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | $36.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $102.01 | $2.18 |
| 52 Week High | $190.56 | $9.75 |
| Indicator | FORTY | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 54.31 |
| Support Level | $101.61 | $5.26 |
| Resistance Level | $134.92 | $6.37 |
| Average True Range (ATR) | 0.92 | 0.36 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 29.96 | 47.09 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.